PL-3994 for Congestive Heart Failure Indications

PL-3994, discovered and developed by scientists at Palatin Technologies, is a natriuretic peptide receptor A (NPRA) agonist compound.  Developed for treatment of both acute congestive heart failure (CHF) and chronic heart failure, including worsening chronic heart failure, PL-3994 has successfully completed both a Phase 1 and Phase 2a trial. 

Over 5 million Americans suffer from CHF, with 550,000 new cases of CHF diagnosed each year – statistics that will only increase with the aging of the population.  Despite the treatment of CHF with multiple drugs, almost all CHF patients will experience at least one episode of acute CHF that requires treatment with intravenous medications in the hospital. Congestive heart failure has tremendous human and financial costs.

PL-3994 is a synthetic molecule, incorporating a novel and proprietary amino acid mimetic developed by Palatin Technologies.  PL-3994 has an extended half-life, with reduced affinity for natriuretic peptide clearance receptors and increased resistance to neutral endopeptidase, an endogenous enzyme that degrades natriuretic peptides. The result is a drug with improved pharmacokinetic and pharmacodynamic properties.

For more information on PL-3994 for CHF, download the fact sheet.